On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company based in Lexington, Massachusetts, reported significant amendments to its financial structure. The company disclosed the conversion of $15.0 million of its outstanding debt into equity with CRG Servicing LLC, resulting in the issuance of 3,280,618 shares of Common Stock and 17,146.48 shares of Series A Convertible Preferred Stock. This follows a similar transaction on July 3, 2023, where $10.0 million of debt was converted into 483,457 shares of Common Stock and 93,297.26 shares of Series B Convertible Preferred Stock. The recent amendments involved the removal of beneficial ownership limitations, allowing for the conversion of all outstanding Series A and Series B Preferred Stock into 1,824,800 shares of Common Stock. Consequently, CRG now owns approximately 69% of T2 Biosystems' outstanding shares. The company's common stock is traded on the Nasdaq Global Market under the symbol TTOO.

On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company based in Lexington, Massachusetts, reported significant amendments to its financial structure. The company disclosed the conversion of $15.0 million of its outstanding debt into equity with CRG Servicing LLC, resulting in the issuance of 3,280,618 shares of Common Stock and 17,146.48 shares of Series A Convertible Preferred Stock. This follows a similar transaction on July 3, 2023, where $10.0 million of debt was converted into 483,457 shares of Common Stock and 93,297.26 shares of Series B Convertible Preferred Stock. The recent amendments involved the removal of beneficial ownership limitations, allowing for the conversion of all outstanding Series A and Series B Preferred Stock into 1,824,800 shares of Common Stock. Consequently, CRG now owns approximately 69% of T2 Biosystems' outstanding shares. The company's common stock is traded on the Nasdaq Global Market under the symbol TTOO.